Puzo Michael J acquired a new stake in Eli Lilly and Co (NYSE:LLY) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 6,261 shares of the company’s stock, valued at approximately $529,000.
Other large investors also recently bought and sold shares of the company. Accredited Investors Inc. lifted its holdings in Eli Lilly and by 0.4% in the 2nd quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock valued at $268,000 after purchasing an additional 14 shares in the last quarter. Sfmg LLC lifted its holdings in Eli Lilly and by 0.5% in the 2nd quarter. Sfmg LLC now owns 4,258 shares of the company’s stock valued at $350,000 after purchasing an additional 20 shares in the last quarter. Jackson Grant Investment Advisers Inc. lifted its holdings in shares of Eli Lilly and by 0.7% during the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 3,647 shares of the company’s stock worth $300,000 after acquiring an additional 24 shares during the period. YorkBridge Wealth Partners LLC lifted its holdings in shares of Eli Lilly and by 0.8% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 3,199 shares of the company’s stock worth $265,000 after acquiring an additional 24 shares during the period. Finally, BSW Wealth Partners lifted its holdings in shares of Eli Lilly and by 0.6% during the 2nd quarter. BSW Wealth Partners now owns 4,774 shares of the company’s stock worth $393,000 after acquiring an additional 27 shares during the period. 76.20% of the stock is currently owned by institutional investors and hedge funds.
Several brokerages have recently weighed in on LLY. BMO Capital Markets set a $73.00 price objective on shares of Eli Lilly and and gave the stock a “sell” rating in a report on Tuesday, December 5th. Credit Suisse Group restated a “hold” rating and issued a $80.00 price target on shares of Eli Lilly and in a report on Friday, February 2nd. Leerink Swann raised their price target on shares of Eli Lilly and from $92.00 to $93.00 and gave the company a “market perform” rating in a report on Monday, October 23rd. Argus upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and raised their price target for the company from $85.52 to $115.00 in a report on Friday, January 5th. Finally, Jefferies Group set a $100.00 price objective on shares of Eli Lilly and and gave the company a “buy” rating in a research report on Tuesday, January 16th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $92.02.
Eli Lilly and Co (NYSE LLY) traded down $0.07 during trading hours on Monday, reaching $76.16. The company had a trading volume of 2,968,315 shares, compared to its average volume of 5,352,852. The firm has a market capitalization of $83,940.00, a price-to-earnings ratio of -381.85, a P/E/G ratio of 1.39 and a beta of 0.23. Eli Lilly and Co has a 1 year low of $73.69 and a 1 year high of $89.09. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66.
Eli Lilly and (NYSE:LLY) last released its earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.08 by $0.06. The firm had revenue of $6.16 billion for the quarter, compared to analyst estimates of $5.93 billion. Eli Lilly and had a positive return on equity of 31.44% and a negative net margin of 0.89%. Eli Lilly and’s revenue was up 7.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.95 earnings per share. equities analysts anticipate that Eli Lilly and Co will post 4.88 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be paid a $0.5625 dividend. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $2.25 dividend on an annualized basis and a yield of 2.95%. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s dividend payout ratio (DPR) is currently -1,040.00%.
In other news, SVP Jeffrey N. Simmons sold 12,500 shares of Eli Lilly and stock in a transaction dated Monday, December 11th. The stock was sold at an average price of $86.46, for a total transaction of $1,080,750.00. Following the completion of the sale, the senior vice president now directly owns 124,522 shares in the company, valued at approximately $10,766,172.12. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Susan Mahony sold 36,585 shares of Eli Lilly and stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $86.18, for a total value of $3,152,895.30. Following the sale, the senior vice president now owns 54,885 shares of the company’s stock, valued at $4,729,989.30. The disclosure for this sale can be found here. Insiders sold a total of 259,610 shares of company stock worth $22,727,406 in the last three months. 0.20% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.thelincolnianonline.com/2018/02/12/puzo-michael-j-takes-529000-position-in-eli-lilly-and-co-lly-updated.html.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.